Jade Biosciences (JBIO) Liabilities and Shareholders Equity (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $319.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 312.0% year-over-year to $319.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 210.39% YoY), and the FY2025 full-year result was $349.8 million, up 380.48% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $319.4 million, down from $349.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $349.8 million in Q4 2025 and bottomed at $72.8 million in Q4 2024.
• The 5-year median for Liabilities and Shareholders Equity is $140.9 million (2023), against an average of $159.4 million.
• The widest annual swing landed in 2024, when Liabilities and Shareholders Equity sank 42.87%; it then soared 380.48% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $135.3 million in 2022, then declined by 5.83% to $127.4 million in 2023, then sank by 42.87% to $72.8 million in 2024, then soared by 380.48% to $349.8 million in 2025, then retreated by 8.68% to $319.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $319.4 million (Q1 2026), $349.8 million (Q4 2025), and $202.4 million (Q3 2025), per Business Quant data.

Peer Comparison